• Current

Cipherome, Inc.
homepage |
Cipherome, Inc. is a unique AI-based pharmacogenomics (PGx) and bioinformatics company focused on accurately predicting adverse drug reactions (ADRs) for personalized care. The unique platform supports the decision in clinical trials at eminent clinical sites in domestic and international partnerships. 

SoVarGen Co.,Ltd.
homepage |
SoVarGen is a biotechnology company founded by the faculty of the Korea Advanced Institute of Science and Technology. (Professor Jeong Ho Lee, KAIST). SoVarGen has focused on screening of anti-sense oligonucleotide (ASO) to develop the advanced therapies for in rare developmental brain disorders with novel research performance and achievements in the field of neurogenetics and epilepsy. ‘SVG101’ for epilepsy got the IND allowance of Phase 1 study by KFDA in August 2021. 

Artiva Biotherapeutics, Inc.
homepage |
 Artiva Biotherapeutics established on 2019 is a biotech company focused on ‘Off-the-shelf, allogeneic NK cell therapies.’ Based on ‘AB101’ licensed-in from GC Cells, Artiva has developed and commercialized allogeneic natural killer (NK) cell therapies with large-scale production and CAR-NK platforms. AB101 is on Phase 1/2 of clinical trial with FDA allowance of IND in December 2020. Artiva transferred novel CAR-NK cell therapy candidates to Merck for clinical development and comme

WindMIL Therapeutics
homepage |
WindMIL is a US Biotech company developing ground-breaking immuno-oncology therapeutics employing unprecedented technologies of harnessing the power of bone marrow derived T cells to treat both blood and solid tumors. WindMIL utilizes the unique property of bone marrow, which is a natural reservoir of memory T cells, to develop highly efficient, cancer-fighting warriors. 

맨처음이전 1 다음맨뒤로